DOXAZOSIN AUROVITAS 4 MG TBL NOB 90

What is the maximum co-payment for DOXAZOSIN AUROVITAS?

If the insurance company contributes, the maximum co-payment is 242,07 Kč. The maximum pharmacy price is 379,12 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, but the reimbursement conditions (reporting limit) have not been set.

Does DOXAZOSIN AUROVITAS have a counted co-payment set?

Yes, the medicine has a counted co-payment of 345,00 Kč. Learn more about the protective limit here.

How much does the insurance company pay for one dispensed reimbursed pack?

137,05 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

Doxazosin a terazosin je hrazen:
1) pro léčbu symptomů dolních močových cest na podkladě benigní hyperplazie prostaty,
2) pro léčbu rezistentní hypertenze při nedosažení cílových hodnot krevního tlaku nejméně trojkombinací,
3) pro léčbu sekundární hypertenze při feochromocytomu v předoperační a pooperační léčbě a při inoperabilních stavech,
4) k přípravě před vyšetřením pro podezření na primární hyperaldosteronismus.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe DOXAZOSIN AUROVITAS?

Prescription is not conditional on a medical specialization.

What is the composition of DOXAZOSIN AUROVITAS?

Doxazosin-mesilát (4,84 mg), doxazosin (4 mg), neznámá látka s kódem 20703, laktosa, neznámá látka s kódem 14679, magnesium-stearát. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Which medicines are similar to DOXAZOSIN AUROVITAS?

The medicine belongs to ATC group C02CA04 – DOXAZOSIN. Medicines with the same active substance can be found here.

Who manufactures DOXAZOSIN AUROVITAS?

Aurovitas, spol. s r.o., Praha (CZ)

Is the medicine in shortage?

The latest report from the manufacturer is from 4. 10. 2022. Production was terminated with effect from 30. 9. 2022. The manufacturer lists medicines with the following code as a potential substitute: